Oral contraception and cardiovascular risk factors during adolescence

被引:16
作者
Paulus, D [1 ]
Saint-Remy, A [1 ]
Jeanjean, M [1 ]
机构
[1] Interuniv Assoc Cardiovasc Dis Prevent, B-1200 Brussels, Belgium
关键词
oral contraceptives; cardiovascular risk factors; adolescence;
D O I
10.1016/S0010-7824(00)00159-1
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The objective of the present study was to analyze the pattern of oral contraceptive (OC) use in teenagers and to examine the relationship between OC use and other cardiovascular risk factors. The study was conducted in 24 Belgian secondary schools. Most students (1526 adolescents aged 12-17 years) agreed to participate (participation rate: 83.6%). Smoking, physical activity habits, menarche, and OC use were assessed by a self-administered questionnaire. Total cholesterol level, blood pressure and anthropometric measurements were also measured. Fourteen per cent of mature girls (14%, n = 92) were OC users. Two-thirds of them (66.3%, n = 61) were taking OC which contained either gestodene or desogestrel. Blood pressure and BMI were similar for OC users and non-users. Total cholesterol level was significantly higher in PC users than in non-users (191 mg/dL versus 172 mg/dL). Logistic regression model confirmed the significant influence of OC use on total cholesterol level (OR = 3.08). OC users were also often smokers (39% versus 20% for non-users). In conclusion, the present study has found significant relationships between OC use and cardiovascular risk factors i.e., high total cholesterol and smoking. The first implication is a need for further research on lipoprotein profile in young OC users. Secondly, the combined use of OC and smoking in teenagers calls for preventive actions. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:113 / 116
页数:4
相关论文
共 32 条
  • [1] ORAL-CONTRACEPTIVE TABLETS CONTAINING 20 AND 30 MU-G OF ETHINYL ESTRADIOL WITH 150 MU-G DESOGESTREL - THEIR INFLUENCE ON LIPIDS, LIPOPROTEINS, SEX-HORMONE BINDING GLOBULIN AND TESTOSTERONE
    AKERLUND, M
    ALMSTROM, E
    HOGSTEDT, S
    NABRINK, M
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1994, 73 (02) : 136 - 143
  • [2] Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®)
    Archer, DF
    Maheux, R
    DelConte, A
    O'Brien, FB
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (05) : S39 - S44
  • [3] Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study
    Beral, V
    Hermon, C
    Kay, C
    Hannaford, P
    Darby, SA
    Reeves, G
    [J]. BRITISH MEDICAL JOURNAL, 1999, 318 (7176) : 96 - 100
  • [4] Cerel-Suhl SL, 1999, AM FAM PHYSICIAN, V60, P2073
  • [5] DEMAREST S, 1998, D1998250507 CTR RECH
  • [6] Oral contraceptives and myocardial infarction: results of the MICA case-control study
    Dunn, N
    Thorogood, M
    Faragher, B
    de Caestecker, L
    MacDonald, TM
    McCollum, C
    Thomas, S
    Mann, R
    [J]. BRITISH MEDICAL JOURNAL, 1999, 318 (7198) : 1579 - 1583
  • [7] FARLEY TMM, 1995, LANCET, V346, P1582
  • [8] Hormonal contraception and risk of cardiovascular disease -: An international perspective
    Farley, TMM
    Collins, J
    Schlesselman, JJ
    [J]. CONTRACEPTION, 1998, 57 (03) : 211 - 230
  • [9] Population-based study of risk of venous thromboembolism associated with various oral contraceptives
    Farmer, RDT
    Lawrenson, RA
    Thompson, CR
    Kennedy, JG
    Hambleton, IR
    [J]. LANCET, 1997, 349 (9045) : 83 - 88
  • [10] Felice ME, 1999, PEDIATRICS, V104, P1161